作者: Giulia Bianchi , Luca Gianni
DOI: 10.1007/978-3-0346-0094-1_5
关键词:
摘要: Pertuzumab is a recombinant humanised monoclonal antibody targeting the extracellular domain of human epidermal growth factor receptor 2 (HER-2) to block HER-2 dimerisation with other HER family members. Preclinical pertuzumab data showed activity in number solid tumour types, and synergistic or additive was also observed when combined chemotherapy targeted agents, including trastuzumab erlotinib. has been studied clinical setting, both as monotherapy combination agents variety types. Following encouraging results Phase II trial patients HER-2-positive metastatic breast cancer, this indication become focus attention for further investigation.